Conclusion. In uraemic patients, cyanide detoxication capability is impaired because of a reduced SCN− Background. We previously investigated the factors involved in uraemic neuropathy in patients undergoing clearance, and increased cyanocobalamin synthesis indicates elevation of cyanide pool, which would be regular haemodialysis and found a significant relationship between the severity of vibration sensation related to the development of uraemic neuropathy.
( PCRF ), 30 patients undergoing regular haemodialysis ( HD patients), and 13 healthy volunteers as a control The development mechanisms of uraemic neuropathy group. Nine of the 30 HD patients were smokers. In have not been elucidated. Because clinical improvement addition, in 10 HD patients without smoking habits occurs in patients who receive frequent and adequate and 10 non-smoking healthy volunteers, the proportion dialysis or a successful kidney transplant, the developof each vitamin B 12 analogue in total vitamin B 12 was ment of uraemic neuropathy has been attributed estimated.
to the accumulation of dialysable metabolites [1 ] . Results. The mean serum SCN− level of the 12 PCRF Pathologically, this neuropathy is usually observed as patients (5.1±1.5 mg/ml ) was significantly higher than primary axonal degeneration with secondary segmental that of the control (2.8±0.9 mg/ml ) (P<0.01). The demyelination [2] . Neurotoxic compounds could mean SCN− level before haemodialysis in the 21 non-deplete energy supplies in the axon by inhibiting the smoking HD patients was identical to that in the activities of nerve fibre enzymes that are necessary for PCRF group, whereas the level in the nine smoking energy synthesis, and thus produce pathological HD patients (7.2±1.8 mg/ml ) significantly higher than changes in nerves [2, 3] . Various substances have been that in the non-smoking subgroup (P<0.01). In 16 designated as putative neurotoxins, e.g., guanidine HD patients with methylcobalamin treatment, serum compounds [4] , parathyroid hormone [5] , and myoino-SCN− levels were lower than in those without methyl-sitol [6 ] . cobalamin treatment (4.5±0.5 mg/ml in non-smoking
To investigate the clinical symptoms of uraemic subgroup, P<0.05). And in the methylcobalamin-neuropathy and the underlying mechanisms, we previtreated subgroup (n=5), the proportion of each ously conducted neurological tests, including measurevitamin B 12 analogue in total vitamin B 12 was normal. ment of vibration perception thresholds ( VPTs), in 25 In the untreated subgroup (n=5), the proportion of patients who were receiving haemodialysis, and found cyanocobalamin fraction (10.5±2.6%) was as high as a significant relationship between the severity of vibrathe level in Leber's disease patients, while the propor-tion sensation impairment and the smoking habit [7 ] . tion of methylcobalamin fraction was low. And the Smoking was considered to be the main cause of serum cyanocobalamin level was higher in the treated cyanide exposure in these patients. Administration subgroup.
of methylcobalamin markedly improved the severity of uraemic neuropathy in terms of VPTs [7] . Based would be one of putative uraemic neurotoxins.
Of the 30 HD patients, 16 had received 500 mg of methylco-
The extreme toxicity of cyanide is due to its ready 
Subjects and methods
paired and non-paired comparisons were applied. A P value less than 0.05 was considered statistically significant. We evaluated 55 Japanese subjects in the following three groups: (i) 12 patients with preterminal chronic renal failure ( PCRF group) (CCr 5.1±2.3 ml/min, mean age 55±16.9 Results years, male/female 4/8 ); ( ii) 30 haemodialysis patients ( HD group) who had received regular haemodialysis (mean age Serum levels of thiocyanate (SCN−) 53.0±9.4 years, male/female 12/18), and (iii) 13 volunteers (control group) with normal renal function (mean age As shown in Figure 1 , the mean serum levels of SCN− 51.4±18.4 years, mean creatinine 0.9±0.2 mg/dl, male/ in the 12 PCRF patients (5.1±1.5 mg/ml ) was significfemale 5/8). None of the PCRF and control group subjects antly higher than in the controls (2.8±0.9 mg/ml ) was smoker. Besides smoking, there were no factors which (P<0.01). The mean SCN− level before haemodialysis could result in diÂerent cyanide exposure between the study in the 21 non-smoking HD patients was virtually population. Nine of the 30 HD group patients were smokers: identical to that in the PCRF group, whereas the level for the smoking subgroup (n=9), mean age was 55. 2±3.3 in the nine smoking HD patients significantly exceeded years, male/female 6/3, and the duration of haemodialysis was 86.0±79.0 months; for the non-smoking subgroup (n= that in the non-smoking HD subgroup (P<0.01). In both the smoking and non-smoking HD subgroups, (10.5±2.6%), which is equivalent to the level reported for patients with Leber's disease (non-smoker), and the mean serum levels of SCN− decreased significantly after haemodialysis, i.e. from 7.2±1.8 to the proportion of methylcobalamin fraction was significantly lower (57.2±3.4%) than the controls 3.8±1.0 mg/ml in the smoking subgroup (P<0.01) and from 4.8±0.7 to 3.2±1.1 mg/ml in the non-smoking (67.4±2.1%). In the treated subgroup, the proportions of these two fractions were equivalent to the controls, subgroup (P<0.01).
Among the 30 HD patients, 16 received methylcobal-cyanocobalamin level was elevated (402±208 pg/ml vs 105±40.2 pg/ml in untreated subgroup), and total amin treatment. Because serum SCN− levels vary largely according to the presence or absence of smoking level of vitamin B 12 content was extremely high. habit, eÂects of methylcobalamin on serum SCN− levels should be examined for smoking and non-Discussion smoking subgroups. Among non-smoking HD patients (n=21), SCN− level in the methylcobalamin-treated Cyanide-releasing substances are metabolized into subgroup (n=10) was 4.5±0.5 mg/ml, which was signicyanide ion and its salts which are called cyanide ficantly lower (P<0.05) than 5.2±0.8 mg/ml of the (CN ). CN poisoning may result from the inhalation untreated subgroup (n=11). Among smoking HD of hydrocyanic acid or from the ingestion of soluble patients (n=9), SCN− level in the treated subgroup inorganic cyanide salts or cyanide-releasing substances (n=6) was 7.0±1.8 mg/ml, while it was 7.6±2.1 mg/ml such as cyanamide, cynogen chloride, and nitroprusin the non-treated subgroup (n=3). SCN− level in the side. Parts of many plants (chokecherry, pin cherry, treated subgroup tended to be lower than in the wild black cherry, peach, apricot, bitter almond and untreated subgroup. However, there was no statistical so on) also contain substances such as amygdalin significant diÂerence.
which release cyanide on digestion. Tobacco smoke may also cause chronic CN poisoning. CN diÂuses Proportion of vitamin B 12 analogues in serum of 10 rapidly in the cells, where it can be partly detoxified non-smoking haemodialysis patients, with or without by CN sulphutransferase (known as rhodanese). Some methylcobalamin treatment CN react with cytochrome oxidase. CN are later slowly released from the complex with cytochrome oxidase Table 1 summarizes the proportions of vitamin B 12 analogues in the serum of 10 non-smoking HD patients and then detoxified by rhodanese. This process was considered because blood thiocyanate levels increase and 6 non-smoking healthy volunteers. In the untreated subgroup (without methylcobalamin), the proportion slowly. The majority of CN in vivo is enzymatically converted to SCN−, and excreted in the urine of cyanocobalamin fraction was significantly high ( Figure 2) . The remaining CN is pooled in the body pathway of CN, and as a result the CN pool increases.
This increase would accelerate CN detoxication via and metabolized mainly via two other routes: (i) production of 2-amino-4-thiazolinecarboxylic acid from cyanocobalamin synthesis using vitamin B 12
, and result in an increase in the proportion of cyanocobalamin cystine and CN, and (ii) synthesis of cyanocobalamin (CN-B 12 ) via the combination of CN with some other fraction and a decrease in the proportion of methylcobalamin fraction ( Figure 3 ). Because the evidence was form of vitamin B 12
analogue, such as hydroxycobalamin or methylcobalamin [12] . Though these two routes obtained in non-smoking uraemic patients, there could be a supply of CN-releasing substances besides smokand other pathways function only auxiliary to the main route via thiocyanate, CN detoxication (i.e. synthesis ing, such as exposure to tobacco smoke (secondhand tobacco smoke). All vitamin B 12 analogues are excreted of cyanocobalamin via the combination of CN with some other form of vitamin B 12 analogue, such as in the urine, and their excretion rates do not change under the condition of impaired renal function, while hydroxycobalamin or methylcobalamin) is known to be accelerated in Leber's disease patients. The propor-changes in enzymatic activity of rhodanese in chronic renal failure have not been reported. tion of cyanocobalamin fraction increases in those patients. It is because the CN pool in Leber's disease
In our uraemic patients in the smoking subgroup, serum SCN− levels more increased. That evidence increases due to the decrease of SCN− production. It is diÃcult to monitor the level of serum CN because suggests that CN pool would be increased by smoking and then neuropathy would be induced in uraemia. CN diÂuses rapidly in the cells. We previously tried to monitor the level of serum CN− in 20 haemodialysis Methylcobalamin, the active form of vitamin B 12 , can act as a coenzyme. In a previous study we observed patients in a pilot study by using a modification of the method of Feldstein and Klendshaj [14, 17] , but the that the vibratory sensation in uraemic patients was improved by the intravenous administration of methyllevel was undetectable. Therefore it is considered that measuring the proportion of cyanocobalamin fraction cobalamin [7] . In the present study the proportions of methylcobalamin and cyanocobalamin fractions in the is the only way to indicate the volume of the CN pool.
In our uraemic patients, serum SCN− levels serum were normal and serum SCN− level were low in the methylcobalamin-treated subgroup. This increased, the proportion of cyanocobalamin fraction was markedly increased to the level as high as the indicates that the CN pool decreases in the methylcobalamin-treated subgroup. In addition, patients in levels seen in Leber's disease patients, and the proportion of methylcobalamin fraction also decreased the same group presented elevated serum cyanocobalamin levels. This indicated that cyanocobalamin syn- ( Table 1 ). Our evidence indicates that in chronic renal failure, SCN− is accumulated due to the decrease in thesis accelerated and CN pool decreased in the methylcobalamin-treated subgroup. We considered SCN− clearance. This impairs the major metabolic , and this results an increase of the proportion of cyanocobalamin fraction and a decrease of the proportion of methylcobalamin fraction. If a patient under these conditions is exposed to CN due to smoking, etc., CN supply increases and CN cannot be detoxicated suÃciently; the accumulated CN would induce neuropathy. 
